Q4 2024 Pulse Biosciences Inc Earnings Call Transcript
Key Points
- Pulse Biosciences Inc (PLSE) has made significant progress in early commercialization steps for their percutaneous electrode for soft tissue ablation in benign thyroid diseases.
- The company has received seven FDA clearances and treated 6,000 patients, showcasing a mature platform ready for multiple clinical and regulatory initiatives.
- Pulse Biosciences Inc (PLSE) strengthened its balance sheet by raising $47.9 million in net proceeds through the exercise of warrants.
- The company has a robust portfolio of over 180 issued patents, protecting its unique nanosecond PFA technology.
- Pulse Biosciences Inc (PLSE) has appointed new leadership, including a new CFO and Chief Medical Officer, to drive its strategic initiatives forward.
- The company reported a GAAP net loss of $19.4 million in the fourth quarter of 2024, compared to $11.9 million in the prior year period.
- Total GAAP costs and expenses increased significantly by $7.7 million to $20.3 million, driven by higher non-cash stock-based compensation and other administrative expenses.
- Non-GAAP net loss also increased to $10.4 million in the fourth quarter of 2024, compared to $8.3 million in the prior year period.
- Cash used in the fourth quarter of 2024, excluding net proceeds from financing, totaled $9.3 million, indicating higher operational cash burn.
- The company faces the challenge of scaling its commercial operations and achieving reimbursement for its novel therapies in competitive markets.
Thank you for standing by. My name is Malia, and I will be your conference operator today. At this time, I would like to welcome everyone to the Pulse Biosciencesâ fourth-quarter 2024 earnings conference call. (Operator Instructions)
Please be advised that today's conference is being recorded. I would now like to turn the conference over to Philip Taylor, Investor Relations. Please go ahead, sir.
Thank you, operator. Before we begin, I'd like to inform you that comments and responses to your questions during today's call reflect management's views as of today, March 27, 2025, only and will include forward-looking statements and opinion statements including predictions, estimates, plans, expectations, and other similar information.
Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued earlier today and in our filings with the US Securities and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
